ProCE Banner Activity

Think Tank on Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Clinical Thought

Read our thoughts on incorporating emerging anti-HER2 ADCs into the management of genitourinary, gastrointestinal, and gynecologic malignancies, including insights on HER2 testing, the latest clinical data, and expert management of adverse events.

Released: March 22, 2024

Share

Faculty

Kathleen N. Moore

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Elizabeth R. Plimack

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Zev A. Wainberg

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Kathleen N. Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Associate Director Clinical Research
Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS: consultant/advisor/speaker: Aadi, AstraZeneca, Blueprint, Caris, Duality, Eisai, Genentech/Roche, GlaxoSmithKline, ImmunoGen, Janssen, Lilly, Merck, Mersana, Novartis, Regeneron, Verastem, Zentalis.

Elizabeth R. Plimack, MD, MS, FASCO

Deputy Director
Professor of Medical Oncology
Fox Chase Cancer Center, Temple Health
Philadelphia, Pennsylvania

Elizabeth R. Plimack, MD, MS, FASCO: consultant/advisor/speaker: Astellas, AstraZeneca, Eisai, EMD Serono, IMV, Merck, Pfizer, Seagen/Esquared, Seattle Genetics, Synthekine.

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Zev A. Wainberg, MD: consultant/advisor/speaker: Arcus, Astellas, AstraZeneca, Daiichi Sankyo, Merck, Novartis, Regeneron, Roche/Genentech, Seagen; data and safety monitoring board: AstraZeneca, Daiichi Sankyo, Pfizer.